Cerberus acquires PaxVax majority interest for $105M
December 10, 2015
Cerberus Capital Management has acquired a majority interest in specialty vaccine company PaxVax for $105 million. As part of the transaction, Ignition Growth Capital and other existing investors will remain as minority shareholders in the company. PaxVax is a fully integrated pharmaceutical company that specializes in the development, manufacture and commercialization of vaccines against infectious diseases. In July of last year, the company had raised a $40 million Series B funding round that generated a valuation of $82.7 million.